Successful Treatment of Comorbid SAPHO Syndrome and Hidradenitis Suppurativa with Upadacitinib
DOI:
https://doi.org/10.2340/actadv.v105.44265Keywords:
SAPHO Syndrome, Upadacitinib, Hidradenitis suppurativa, Janus Kinase Inhibitors, autoinflammatory diseasesDownloads
References
Ferraioli M, Levani J, De Luca R, Matucci-Cerinic C, Gattorno M, Guiducci S, et al. What is new and what is next for SAPHO syndrome management: a narrative review. J Clin Med 2025; 14: 1366. DOI: https://doi.org/10.3390/jcm14041366
Sabat R, Jemec GBE, Matusiak Ł, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Prim 2020; 6: 18. DOI: https://doi.org/10.1038/s41572-020-0149-1
Benhamou C, Chamot AM, Kahn MF. Le syndrome synovite–acné–pustulose–hyperostose–ostéite (SAPHO). Ann Dermatol Venereol 1988; 115: 613–618.
Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A. Le syndrome acné pustulose hyperostose ostéite (SAPHO). Résultats d’une enquête nationale. 85 observations. Rev Rhum Mal Osteoartic 1987; 53: 187–196.
Maronese CA, Moltrasio C, Marzano AV. Hidradenitis suppurativa-related autoinflammatory syndromes: an updated review on the clinics, genetics, and treatment of pyoderma gangrenosum, acne and suppurative hidradenitis (PASH), pyogenic arthritis, pyoderma gangrenosum, acne and suppurative hidradenitis (PAPASH), synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO), and rarer forms. Dermatol Clin 2024; 42: 247–265. DOI: https://doi.org/10.1016/j.det.2023.12.004
Firinu D, Barca MP, Lorrai MM, Perra S, Cabras S, Muggianu E, et al. TH17 cells are increased in the peripheral blood of patients with SAPHO syndrome. Autoimmunity 2014; 47: 389–394. DOI: https://doi.org/10.3109/08916934.2014.906582
Yue Q, Ma M, Liu S, Wu Y, Li C. JAKi: can it be used to treat SAPHO syndrome? Int J Rheum Dis 2024; 27: e14930. DOI: https://doi.org/10.1111/1756-185X.14930
Ma M, Lu S, Hou X, Li C. Novel JAK-1 inhibitor upadacitinib as a possible treatment for refractory SAPHO syndrome: a case report. Int J Rheum Dis 2023; 26: 2335–2337. DOI: https://doi.org/10.1111/1756-185X.14774
Tan IJ, Nguyen HN, Wolfe SM, Agarwal P, Cohen BA. Targeted biologic therapies for hidradenitis suppurativa. Int J Mol Sci 2025; 26: 8887. DOI: https://doi.org/10.3390/ijms26188887
Duggan S, Keam SJ. Upadacitinib: first approval. Drugs 2019; 79: 1819–1828. DOI: https://doi.org/10.1007/s40265-019-01211-z
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Deepika Narayanan, Tiffaney Tran, Valeria Duque-Clavijo, Hung Q. Doan, Stephen K. Tyring
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
